Who is Archemix?

Archemix is a biopharmaceutical company committed to the discovery and development of aptamer-based therapeutics. Founded in May 2001, we are located in Cambridge, Massachusetts.

With an experienced management team, world-class scientists and strong financial backing from leading biotech investors, we are leveraging a dominant patent portfolio and proprietary technologies to create a novel class of therapeutics which encompass many of the benefits of small molecule drugs and biotherapeutics. Through both internal programs and alliances with pharmaceutical partners, Archemix is creating better medicines for tomorrow.

Archemix is the biopharmaceutical company leading the development of
aptamers as a new class of directed therapeutics for the prevention and
treatment of chronic and acute disease.

Archemix believes the unique properties of aptamers hold extraordinary
potential in the fast-breaking world of drug discovery and development.
Because of their unequaled specificity for their molecular targets, aptamers
provide a promising alternative to conventional therapeutic approaches.
Aptamers can be used in a wide range of disease areas, including many of
those currently addressed by protein-based therapeutics. Aptamers
demonstrate little to no immunogenicity or toxicity, and can be produced
quickly and economically.

With a portfolio of over 300 patents and patent applications, Archemix holds
the key to the development of aptamer technology and its implications for the
pharmaceutical industry. We are committed to using our expertise to
aggressively pursue drug discovery and development for the benefit of all.